Autolus Therapeutics (AUTL) Expected to Announce Earnings on Thursday

Autolus Therapeutics (NASDAQ:AUTL) is anticipated to release its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect Autolus Therapeutics to post earnings of ($0.29) per share and revenue of $26.2660 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, May 14, 2026 at 8:30 AM ET.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.07). Autolus Therapeutics had a negative return on equity of 99.05% and a negative net margin of 381.40%.The firm had revenue of $24.29 million during the quarter, compared to the consensus estimate of $23.92 million. On average, analysts expect Autolus Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Autolus Therapeutics Trading Up 0.6%

AUTL stock opened at $1.58 on Tuesday. Autolus Therapeutics has a 1-year low of $1.18 and a 1-year high of $2.70. The firm has a market cap of $420.50 million, a P/E ratio of -1.46 and a beta of 1.93. The business’s 50 day moving average is $1.49 and its 200-day moving average is $1.51.

Institutional Investors Weigh In On Autolus Therapeutics

Large investors have recently bought and sold shares of the business. Marex Group plc bought a new stake in Autolus Therapeutics during the 2nd quarter worth approximately $28,000. SmartHarvest Portfolios LLC bought a new stake in Autolus Therapeutics during the 4th quarter worth approximately $43,000. Caitong International Asset Management Co. Ltd acquired a new position in Autolus Therapeutics during the 3rd quarter worth $46,000. Federation des caisses Desjardins du Quebec acquired a new position in Autolus Therapeutics during the 4th quarter worth $62,000. Finally, Invesco Ltd. lifted its holdings in Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company’s stock worth $51,000 after buying an additional 11,381 shares in the last quarter. 72.83% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, April 9th. Jefferies Financial Group upgraded Autolus Therapeutics to a “strong-buy” rating in a research note on Monday, April 20th. Zacks Research upgraded Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, March 13th. Truist Financial upgraded Autolus Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, Weiss Ratings upgraded Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. Two equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $8.50.

Autolus Therapeutics Company Profile

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.